Pancreatic Cancer Surveillance in CDKN2A and Other High Risk Mutation Carriers
- Conditions
- Pancreatic cancer
- Registration Number
- NL-OMON27120
- Lead Sponsor
- eiden University Medical Center
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 280
Inclusion Criteria
Participating in the PC surveillance program, which requires:
•A proven CDKN2A or LKB1/STK11 mutation and = 40 years old
•A proven BRCA1, BRCA2, PALB2, ATM, MLH1, MSH2, or MSH6 mutation with at least one affected first degree blood relative with pancreatic cancer and = 45 years old.
•Screening for all mutation carriers ends at the age of 75 years.
Exclusion Criteria
•Comorbidity leading to an impaired physical performance (World health organization (WHO) performance status 3-4) or mental retardation
•Life expectancy < 5 years.
•Very limited understanding of the Dutch or English language to be able to make an informed choice.
•No informed consent.
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The 5-year survival rate of patients with a CDKN2A mutation undergoing surveillance who develop PC.
- Secondary Outcome Measures
Name Time Method